<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="333">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156814</url>
  </required_header>
  <id_info>
    <org_study_id>ESDYC001</org_study_id>
    <nct_id>NCT05156814</nct_id>
  </id_info>
  <brief_title>Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women</brief_title>
  <acronym>Violet</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Open-label, Comparative Study in Three Parallel Groups to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone (Femoston® 1 or Femoston® 2, Coated Tablets) and the Combination Therapy of Dydrogesterone (Duphaston®, Coated Tablets) Plus Estradiol (Divigel, Gel for Topical Application, 0.1%) and Monotherapy With Cimicifuga Racemosa Rhizomatum Extract (Klimadynon®) in Perimenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scientific Research Institute of Public Health, Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scientific Research Institute of Public Health, Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain new data allowing personalizing continuous hormonal therapy in perimenopausal women&#xD;
      in Russia, the following clinical study is going to be conducted in the Russian Federation:&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the average number of &quot;hot flashes&quot; per day* as percentages according to data from the patient diary after 84 days (3 cycles) since the initiation of treatment compared to baseline (Visit 0).</measure>
    <time_frame>84 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the total score on the Greene Scale at the end of the therapy (364 days) compared to baseline.</measure>
    <time_frame>364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of &quot;hot flashes&quot; after 84 days since the initiation of treatment.</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the intensity of of menopausal symptoms calculated using the Menopause Rating Scale (MRS) after 84, 168, and 364 days since the treatment initiation compared to baseline (Visit 0).</measure>
    <time_frame>84 days, 168 days, 364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes according to the Greene Climacteric Scale in each of the 4 subscales after 84, 168, and 364 days since the initiation of treatment compared to baseline (Visit 0).</measure>
    <time_frame>84 days, 168 days, 364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes according to the &quot;Hot Flush&quot; Related Daily Interference Scale (HFRDIS) after 84, 168, and 364 days since the initiation of treatment compared to baseline (Visit 0).</measure>
    <time_frame>84 days, 168 days, 364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average treatment satisfaction score according to the Likert Scale after 84, 168, and 364 days since the initiation of treatment.</measure>
    <time_frame>84 days, 168 days, 364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the adipose tissue according to densitometry results after 364 days of treatment compared to baseline (Visit 0).</measure>
    <time_frame>364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the waist circumference after 364 days of treatment compared to baseline (Visit 0).</measure>
    <time_frame>364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the bone tissue according to densitometry results after 364 days of treatment compared to baseline (Visit 0).</measure>
    <time_frame>364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the bone resorption marker β-Cross laps after 364 days of treatment compared to baseline (Visit 0).</measure>
    <time_frame>364 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the bone formation marker (P1NP) after 364 days of treatment compared to baseline (Visit 0).</measure>
    <time_frame>364 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Women in Perimenopause With Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Fixed-dose Combination (FDC) estradiol / dydrogesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy with estradiol and dydrogesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duphaston®, 10 mg and Divigel, 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-hormonal therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cimicifuga racemosa rhizomatum extract (Klimadynon®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC estradiol / dydrogesterone</intervention_name>
    <description>Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)</description>
    <arm_group_label>Fixed-dose Combination (FDC) estradiol / dydrogesterone</arm_group_label>
    <other_name>Femoston® 1, Femoston® 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination therapy with estradiol and dydrogesterone</intervention_name>
    <description>Duphaston®, 10 mg and Divigel, 0.1%</description>
    <arm_group_label>Combination therapy with estradiol and dydrogesterone</arm_group_label>
    <other_name>Duphaston® and Divigel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-hormonal therapy</intervention_name>
    <description>Cimicifuga racemosa rhizomatum extract</description>
    <arm_group_label>non-hormonal therapy</arm_group_label>
    <other_name>Klimadynon®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Caucasian women in perimenopause (STRAW -1/ +1a) with an intact uterus.&#xD;
&#xD;
          2. Age from 40 to 55 years old as of the time of screening.&#xD;
&#xD;
          3. Absence of natural menstruations within 4 months, but not longer than for 12 months.&#xD;
&#xD;
          4. 50 or more episodes of &quot;hot flashes&quot; in the last 7 days according to the patient diary&#xD;
             (at the screening).&#xD;
&#xD;
          5. Patients scoring more than 12 points on the Greene Scale.&#xD;
&#xD;
          6. Follicle-Stimulating Hormone (FSH) levels more than 25 IU/L, estradiol levels less&#xD;
             than 190 pmol/L.&#xD;
&#xD;
          7. Consent to the use of barrier methods of contraception.&#xD;
&#xD;
          8. Body mass index &lt;30 kg / m2.&#xD;
&#xD;
          9. Signed Informed Consent Form.&#xD;
&#xD;
         10. Mammography performed within 6 months prior to inclusion in the study.&#xD;
&#xD;
         11. Absence of clinically significant deviations according to the results of medical&#xD;
             examination: physical examination (including assessment of the state of the mammary&#xD;
             glands), measurement of indicators of vital body functions (blood pressure, heart&#xD;
             rate, respiratory rate and body temperature) and gynecological examination.&#xD;
&#xD;
         12. The patient's consent to perform all research procedures and adhere to all&#xD;
             restrictions provided for by the research protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Smoking.&#xD;
&#xD;
          2. Administration of drugs from the prohibited therapy list.&#xD;
&#xD;
          3. Known hypersensitivity to estradiol, dydrogesterone, to the active component of the&#xD;
             drug Klimadynon® (dry extract of rhizomes of cimicifuga racemose) or to any of the&#xD;
             excipients of the study drugs.&#xD;
&#xD;
          4. Pregnancy and breastfeeding.&#xD;
&#xD;
          5. Abnormal uterine bleeding from the vagina of unclear etiology within 12 months before&#xD;
             the screening stage.&#xD;
&#xD;
          6. Breast cancer (diagnosed, suspected, or past).&#xD;
&#xD;
          7. Estrogen-dependent malignancies of the sex organs, including endometrial cancer&#xD;
             (diagnosed, suspected, or past).&#xD;
&#xD;
          8. Known or suspected progestogen-dependent neoplasms (e.g. meningioma).&#xD;
&#xD;
          9. Untreated endometrial hyperplasia.&#xD;
&#xD;
         10. Venous and arterial thrombosis/thromboembolism, currently or in history (including&#xD;
             deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic or&#xD;
             hemorrhagic stroke; angina pectoris, transient ischemic attack).&#xD;
&#xD;
         11. Diagnosed hereditary or acquired predisposition to arterial or venous&#xD;
             thrombosis/thromboembolism (eg, hyperhomocysteinemia, deficiency of protein C, protein&#xD;
             S or antithrombin III, the presence of antiphospholipid antibodies).&#xD;
&#xD;
         12. Acute or chronic liver disease in history (in case of deviation from a norm of liver&#xD;
             function indicators); benign and malignant liver tumors (including hemangioma,&#xD;
             adenoma, liver cancer) or an increase in Alanine Aminotransferase (ALT) and Aspartate&#xD;
             Aminotransferase (AST) activity detected during screening by more than 1.5 times&#xD;
             relative to the upper limit of normal.&#xD;
&#xD;
         13. Porphyria.&#xD;
&#xD;
         14. Epilepsy.&#xD;
&#xD;
         15. Brain disorders and traumas.&#xD;
&#xD;
         16. Galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.&#xD;
&#xD;
         17. Cholestatic jaundice and/or severe cholestatic itching (especially during a previous&#xD;
             pregnancy or sex hormone intake).&#xD;
&#xD;
         18. Uncontrolled hypertension.&#xD;
&#xD;
         19. Diabetes mellitus.&#xD;
&#xD;
         20. Adenomyosis grade &gt;3 and uterine myoma (more than 3 nodes with an intermuscular or&#xD;
             subserous arrangement with a diameter of more than 3 cm) and / or centripetal&#xD;
             growth/submucous node location.&#xD;
&#xD;
         21. Cholelithiasis.&#xD;
&#xD;
         22. Systemic lupus erythematosus.&#xD;
&#xD;
         23. Bronchial asthma.&#xD;
&#xD;
         24. Otosclerosis.&#xD;
&#xD;
         25. Known renal or hepatic insufficiency.&#xD;
&#xD;
         26. Ovarian cysts &gt;6 mm based on results of ultrasound scanning.&#xD;
&#xD;
         27. Endometrial thickness ≥5 mm according to transvaginal ultrasound.&#xD;
&#xD;
         28. Migraine headache or a history of severe migraine-type headaches.&#xD;
&#xD;
         29. Other medical conditions which could interfere with the study-related procedures&#xD;
             and/or influence the efficacy of the study drug.&#xD;
&#xD;
         30. Simultaneous intake of excluded drugs.&#xD;
&#xD;
         31. Participation in any other clinical study within 3 months before screening.&#xD;
&#xD;
         32. Pathological result of smear for cytology (PAP test) and Human papillomavirus (HPV)&#xD;
             test.&#xD;
&#xD;
         33. The use of estrogens or combination drugs for hormone replacement therapy (HRT) within&#xD;
             6 months before the start of the study.&#xD;
&#xD;
         34. Higher risk of thromboembolic complications due to prolonged immobilization for 2&#xD;
             weeks before the screening stage (for example, as a result of trauma or surgery).&#xD;
&#xD;
         35. Previous major surgical interventions (including abdominal) within 6 months before the&#xD;
             start of the study.&#xD;
&#xD;
         36. Tumor of the pituitary gland.&#xD;
&#xD;
         37. Severe pathology of the cardiovascular system: complicated lesions of the valvular&#xD;
             apparatus of the heart, uncontrolled drug arrhythmia, chronic heart failure I - IV&#xD;
             functional class.&#xD;
&#xD;
         38. Sickle cell anemia.&#xD;
&#xD;
         39. Congenital hyperbilirubinemia (Gilbert, Steven-Johnson and Rotor).&#xD;
&#xD;
         40. A history of pancreatitis with severe hypertriglyceridemia.&#xD;
&#xD;
         41. Polyp in the uterine cavity.&#xD;
&#xD;
         42. Use of any drugs in the form of prolonged-release injections or implants within 3&#xD;
             months before the screening stage.&#xD;
&#xD;
         43. A history of any other malignant neoplasms within 5 years prior to the study, with the&#xD;
             exception of adequately treated squamous cell skin cancer.&#xD;
&#xD;
         44. Anamnestic data on any clinically significant disease of the kidneys, lungs,&#xD;
             gastrointestinal tract, skin and subcutaneous tissues, musculoskeletal system, blood&#xD;
             and lymphatic system, nervous system.&#xD;
&#xD;
         45. Positive blood test for HIV, hepatitis B and C, syphilis.&#xD;
&#xD;
         46. Alcoholism, drug addiction in history.&#xD;
&#xD;
         47. Prior endometrial ablation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatiana Semykina</last_name>
    <phone>+79219565085</phone>
    <email>ts@publichealthinstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Sias</last_name>
    <phone>+7 916 211 8811</phone>
    <email>lek@publichealthinstitute.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hot flashes</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Dydrogesterone</keyword>
  <keyword>Cimicifuga racemosa</keyword>
  <keyword>Perimenopausal Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

